Ampio Pharmaceuticals (AMPE +4%) trades up after announcing its begun dosing the first patient...

|About: Ampio Pharmaceuticals, Inc. (AMPE)|By:, SA News Editor

Ampio Pharmaceuticals (AMPE +4%) trades up after announcing its begun dosing the first patient in its clinical trial of Optina, a treatment for diabetic macular edema. The trial will evaluate the drug in adults with recent onset of the disease. Last year, the FDA granted Optina 505(b)(2) status. Drugs under this designated pathway can be approved on a single trial.